Eli Lilly | LLY - SCHULD





SCHULD Veränderung Datum
AbbVie USD 70.82B 2.04B 2026-06
Abbott USD 34.05B 20.19B 2026-03
ALKERMES USD 1.58B 1.51B 2026-03
Amgen USD 57.3B 19M 2026-06
AstraZeneca USD 32.24B 1.68B 2026-06
Baxter International USD 9.67B 20M 2026-06
Biogen USD 7.69B 398.3M 2026-09
Bristol-Myers Squibb USD 42.88B 2.18B 2026-09
Coherus Biosciences USD 294.92M 1.25M 2025-03
Drreddys Laboratories INR 72.29B 5.05B 2026-09
Eli Lilly USD 54.91B 11.54B 2026-06
Gilead Sciences USD 26.25B 4.07B 2026-06
GlaxoSmithKline GBP 18.24B 818M 2026-06
Glaxosmithkline GBP 23.7B 4.65B 2026-09
J&J USD 49.04B 5.95B 2026-06
Medtronic USD 28.15B 192M 2026-06
Merck USD 53.91B 4.79B 2026-06
Neurocrine Biosciences USD 401.8M 4.4M 2026-06
Novartis USD 49.01B 2.02B 2026-06
Novartis USD 48.31B 1.31B 2026-09
Novo Nordisk DKK 118.72B 61.75B 2025-03
Perrigo USD 3.29B 337.7M 2026-06
Pfizer USD 63.19B 536M 2026-06
Phibro Animal Health USD 474.17M 730K 2024-09
Prestige Brands USD 2.07B 1.02B 2026-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 23.58B 3.56B 2026-06
Sanofi EUR 23.58B 3.56B 2026-06
United Therapeutics USD 200M 100M 2025-03
Zoetis USD 9.24B 0 2026-06